HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Uveal melanoma therapy on the horizon?

Abstract
A phase II trial of the MEK inhibitor selumetinib offers hope for patients with metastatic uveal melanoma, a rare and fatal eye cancer.
Authors
JournalCancer discovery (Cancer Discov) Vol. 4 Issue 9 Pg. OF6 (Sep 2014) ISSN: 2159-8290 [Electronic] United States
PMID25185205 (Publication Type: Journal Article, Comment)
Copyright©2014 American Association for Cancer Research.
Chemical References
  • Antineoplastic Agents, Alkylating
  • Benzimidazoles
  • Dacarbazine
Topics
  • Antineoplastic Agents, Alkylating (therapeutic use)
  • Benzimidazoles (therapeutic use)
  • Dacarbazine (analogs & derivatives, therapeutic use)
  • Female
  • Humans
  • Male
  • Melanoma (drug therapy)
  • Uveal Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: